Roche, Chiasma ink deal on gland disorder treatment
ZURICH Feb 18 (Reuters) - Swiss drugmaker Roche said on Monday it would work with privately held Chiasma to develop and market a treatment for growth hormone disorders in a deal worth almost $600 million in upfront and milestone payments.
The companies will work on the development Octreolin, an oral form of a growth hormone treatment now only sold in injections. Octreolin is currently in a late stage trial for the treatment of a condition caused by excessive growth hormone.
Roche will make an upfront payment of $65 million to Chiasma, further milestone payments of up to $530 million and double digit royalties on net sales of Octreolin.
(Reporting by Martin de Sa'Pinto)
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source
- Radar showed missing plane may have turned back: Malaysia military
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Malaysian plane presumed crashed; questions over false IDs |
- Merkel raps Putin as Russian forces tighten grip on Crimea |